Leyh, C.; Ehmer, U.; Roessler, D.; Philipp, A.B.; Reiter, F.P.; Jeliazkova, P.; Jochheim, L.S.; Jeschke, M.; Hammig, J.; Ludwig, J.M.;
et al. Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis. Cancers 2022, 14, 1975.
https://doi.org/10.3390/cancers14081975
AMA Style
Leyh C, Ehmer U, Roessler D, Philipp AB, Reiter FP, Jeliazkova P, Jochheim LS, Jeschke M, Hammig J, Ludwig JM,
et al. Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis. Cancers. 2022; 14(8):1975.
https://doi.org/10.3390/cancers14081975
Chicago/Turabian Style
Leyh, Catherine, Ursula Ehmer, Daniel Roessler, Alexander B. Philipp, Florian P. Reiter, Petia Jeliazkova, Leonie S. Jochheim, Matthias Jeschke, Janina Hammig, Johannes M. Ludwig,
and et al. 2022. "Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis" Cancers 14, no. 8: 1975.
https://doi.org/10.3390/cancers14081975
APA Style
Leyh, C., Ehmer, U., Roessler, D., Philipp, A. B., Reiter, F. P., Jeliazkova, P., Jochheim, L. S., Jeschke, M., Hammig, J., Ludwig, J. M., Theysohn, J. M., Geier, A., & Lange, C. M.
(2022). Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis. Cancers, 14(8), 1975.
https://doi.org/10.3390/cancers14081975